Nyrada, Inc. · ASX:NYR
Nyrada — Investor Presentation (January 2020)
16 slides from Nyrada's investor presentation, Jan 17, 2020
Slide 1: Improving Lives, Offering Hope
For personal use only Improving Lives, Offering Hope Developing New Therapies for Cardiovascular and Neurological Disorders Corporate Presentation (ASX:NYR) January 2020 1
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe for securities
Slide 3: Nyrada Introduction and Vision
Nyrada Introduction and Vision For personal use only Intro • Nyrada listed on the Australian Securities Exchange 16 January 2020 (ASX:NYR) Vision To become a high-growth pharmaceutical company, specialising in drug discovery and early-stage development in areas of substantial unmet clinical need, wh
Slide 4: Program 1: Cholesterol-lowering drug
Program 1: Cholesterol-lowering drug For personal use only Aim Single-pill treatment for high cholesterol (PCSK9i + Statin) Problem 43 million ADULTS IN THE US have high LDL cholesterol and are taking statin medication US$317 billion CARDIOVASCULAR DISEASE COSTS IN THE US Including healthcare servic
Slide 5: Current Standard of Care
Current Standard of Care For personal use only Standard Statin drugs block the liver’s ability to make LDL-cholesterol Treatment (Global sales of statin drugs in 2017 estimated to be US$19 billion) However… • Many patients are statin intolerant (up to 20%) • Many patients do not achieve target ’heal
Slide 6: PCSK9: Beyond Statin Therapy
PCSK9: Beyond Statin Therapy For personal use only Cholesterol and PCSK9 Current PCSK9 inhibitors PCSK9, a protein found in blood, plays a key role in regulating LDL cholesterol levels Statins increase PCSK9 blood levels: This accounts for their failure to work optimally for many patients Two PCSK9-
Slide 7: Our Cholesterol-Lowering Solution
Our Cholesterol-Lowering Solution For personal use only What’s Unique As far as we are aware, Nyrada is only 1 of 2 companies developing a small molecule PCSK9-inhibitor. Our aim is that our drug will pave the way for a single pill solution, for effective lowering of high LDL cholesterol. ✓ Benefit
Slide 8: Cholesterol-Lowering Drug: Market Overview (US)
Cholesterol-Lowering Drug: Market Overview (US) For personal use only Patient and Market Need Large potential market – Approx. 18 million people in the U.S. with atherosclerosis who live with elevated LDL levels despite taking maximally tolerated statin therapy — including individuals considered sta
Slide 9: Program 2: Brain Injury Drug
Program 2: Brain Injury Drug For personal use only Aim Treatment for Stroke and Traumatic Brain Injury Problem Stroke Traumatic Brain Injury 0.8 million 2.8 million PEOPLE EACH YEAR PEOPLE EACH YEAR suffer a stroke in the US sustain a TBI in the US STROKE COSTS TBI COSTS Direct medical costs and ind
Slide 10: Brain Injury Solution
Brain Injury Solution For personal use only Current Treatment Options Largely unmet clinical need • Clot-buster drugs for treatment of ischemic stroke (Only suitable for approx. 10% of acute stroke patients due to short (<4.5 hr) therapeutic window) • Drug treatments for brain injury limited to diur
Slide 11: Brain Injury Drug: Market Overview (US)
Brain Injury Drug: Market Overview (US) For personal use only Stroke Stroke emergency room visits per year in the US Approx. 650k Patients who present within nominal 12-hour therapeutic window (>75%) Approx. 490k Clot-buster Alteplase sales approx. US$1.2 billion in 2017; cost per patient approx. US
Slide 12: Company Program Status
Company Program Status For personal use only • Proof-of-concept established for both the cholesterol-lowering and neuroprotection programs • Lead optimisation well-advanced − Composition of matter patents have been lodged (but not yet granted) for both programs − Key publication submitted (PCSK9 inh
Slide 13: Board of Directors
Board of Directors For personal use only Nyrada operates under the direction of a board of international calibre, with a track record in founding and realizing the value of biotech companies Mr John Moore John Moore currently serves as Non-Executive Chairman of Trialogics, a clinical trial informati
Slide 14: Board of Directors (continued)
Board of Directors (continued) For personal use only Nyrada operates under the direction of a board of international calibre, with a track record in founding and realizing the value of biotech companies Mr Marcus Marcus Frampton is CIO of Alaska Permanent Fund Corporation (APFC), a $65 billion sover
Slide 15: Scientific Advisory Board
Scientific Advisory Board For personal use only Nyrada benefits from an international team of experts with deep experience in drug development to advise its board and management Scientia Professor Gary Housley is the Chair of the Nyrada Inc Scientific Advisory Board. Prof. Housley holds the Chair of
Slide 16: For personal use only
www.nyrada.com For personal use only • Large and under-served therapeutic areas • Proof of concept data from cell and animal models • Right team assembled to execute on strategic objectives USA John Moore - Chairman John.Moore@nyrada.com Dr Graham Kelly Graham.Kelly@nyrada.com Australia James Bonnar